| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2015-11-679571 |
| P698 | PubMed publication ID | 26608331 |
| P50 | author | Ilyas Chachoua | Q91560391 |
| William Vainchenker | Q3569009 | ||
| Stefan N Constantinescu | Q38322237 | ||
| Jean-Luc Villeval | Q39976701 | ||
| Isabelle Plo | Q55807412 | ||
| Hana Raslova | Q59544856 | ||
| P2093 | author name string | Micheline Tulliez | |
| Robert Kralovics | |||
| Christian Pecquet | |||
| Caroline Marty | |||
| Harini Nivarthi | |||
| Mira El-Khoury | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1317-1324 | |
| P577 | publication date | 2015-11-25 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis | |
| P478 | volume | 127 |
| Q95492528 | Q95492528 |
| Q37740931 | A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. |
| Q90788191 | AKT activation is a feature of CALR mutant myeloproliferative neoplasms |
| Q33573793 | Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms |
| Q42334359 | Absence of CALR mutations in JAK2-negative polycythemia. |
| Q59332844 | Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis |
| Q33443580 | Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. |
| Q39321106 | Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. |
| Q60103644 | Bone marrow-specific loss of induces myeloproliferative neoplasm with features resembling human myelofibrosis |
| Q47347862 | CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles |
| Q92289300 | CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms |
| Q92092554 | Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants |
| Q98177138 | Calreticulin and cancer |
| Q100307043 | Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN |
| Q90702243 | Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms |
| Q42253829 | Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus |
| Q41955541 | Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib |
| Q38771057 | Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion |
| Q60222307 | Captopril mitigates splenomegaly and myelofibrosis in the Gata1 murine model of myelofibrosis |
| Q58801187 | Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors |
| Q49485576 | Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. |
| Q37679175 | Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. |
| Q96640873 | Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms |
| Q36169641 | Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment |
| Q47209528 | Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. |
| Q45874813 | Endoplasmic reticulum in health and disease: the 12th International Calreticulin Workshop, Delphi, Greece |
| Q39869997 | Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group |
| Q39306368 | Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery |
| Q37397491 | Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish |
| Q41684028 | Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis |
| Q26770869 | Genomic landscape of megakaryopoiesis and platelet function defects |
| Q89267519 | Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation |
| Q33779135 | Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia |
| Q38660742 | Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients |
| Q48109284 | JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. |
| Q38684435 | JAK2 inhibitors for myeloproliferative neoplasms: what is next? |
| Q90037559 | JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling |
| Q63728935 | JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation |
| Q42794052 | JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms |
| Q93023502 | Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development |
| Q38798560 | Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis |
| Q64100874 | Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis |
| Q38984558 | Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review |
| Q37555785 | Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms |
| Q38978004 | Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms |
| Q30244032 | Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia |
| Q58761454 | Multiple Roles of Glycans in Hematological Malignancies |
| Q36853951 | Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation |
| Q94555011 | Mutant Calreticulin in the Myeloproliferative Neoplasms |
| Q47111104 | Mutant calreticulin causes essential thrombocythemia |
| Q90338526 | Mutant calreticulin in myeloproliferative neoplasms |
| Q59133186 | Mutant molecular chaperone activates cytokine receptor as a homomultimer |
| Q49721968 | Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. |
| Q39027848 | Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions |
| Q50072000 | Mutations in myeloproliferative neoplasms - their significance and clinical use. |
| Q39118859 | Myeloproliferative neoplasm stem cells. |
| Q49989025 | Myeloproliferative neoplasms: from origins to outcomes. |
| Q58793895 | Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts |
| Q53052368 | Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms. |
| Q39457113 | Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. |
| Q38699339 | Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). |
| Q53204648 | Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. |
| Q28069839 | Pathophysiological Significance of Store-Operated Calcium Entry in Megakaryocyte Function: Opening New Paths for Understanding the Role of Calcium in Thrombopoiesis |
| Q38717569 | Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. |
| Q49834487 | Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. |
| Q92209332 | Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice |
| Q26748543 | Recent advances in understanding myelofibrosis and essential thrombocythemia |
| Q59799223 | Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis |
| Q39015118 | Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis |
| Q64074909 | Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms |
| Q49580473 | SOHO State-of-the-Art Update and Next Questions: MPN. |
| Q89457655 | Secreted calreticulin mutants subvert anticancer immunosurveillance |
| Q33441445 | Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia |
| Q91595285 | Somatic mutations and cell identity linked by Genotyping of Transcriptomes |
| Q87992891 | Somatic mutations of calreticulin in myeloproliferative neoplasms |
| Q37638779 | Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease |
| Q99406585 | Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis |
| Q93080041 | Targeting the CALR interactome in myeloproliferative neoplasms |
| Q33433481 | The Calreticulin gene and myeloproliferative neoplasms |
| Q49442070 | The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms |
| Q64085216 | The Role of New Technologies in Myeloproliferative Neoplasms |
| Q33440994 | The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin |
| Q54105420 | The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis. |
| Q42365043 | Thrombopoietin receptor is required for the oncogenic function of CALR mutants. |
| Q40392738 | Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm |
| Q42089573 | miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. |
Search more.